Treatments in Phase 3 Trials
Biologics
Name: BCD-057
Indication: Psoriasis
- BIOCAD
- Biosimilar for Humira (adalimumab)
- TNF-alpha inhibitor
Name: BCD-085
Indication: Psoriasis and PsA
- BIOCAD
- IL-17 inhibitor
Name: BI695501
Indication: Psoriasis
- Boehreinger Ingelheim
- Biosimilar for Humira (adalimumab)
- TNF-alpha inhibitor
Name: Bimekizumab (UCB4940)
Indication: Psoriasis and PsA
- UCB
- IL-17A and IL-17F inhibitor
Name: CHS-1420
Indication: Psoriasis
- Coherus Biosciences
- Biosimilar for Humira (adalimumab)
- TNF-alpha inhibitor
Name: GP2017
Indication: Psoriasis
- Sandoz
- Biosimilar for Humira (adalimumab)
- TNF-alpha inhibitor
Name: PF-06438179
Indication: Psoriasis
- Pfizer
- Biosimilar for Remicade (infliximab)
- TNF-alpha inhibitor
Oral Treatments
Name: BMS-986165 (deucravacitinib)
Indication: Psoriasis and PsA
- Bristol-Myers Squibb
- TYK2 kinase inhibitor
Name: CF101 (piclidenoson)
Indication: Psoriasis
- Can-Fite BioPharma
- Adenosine A3 receptor inhibitor
Name: Filgotinib (GLPG0634)
Indication: PsA
- Galapagnos NV
- JAK1 inhibitor
Name: LAS41008
Indication: Psoriasis
- Almirall
- Dimethyl fumarate
Name: Serlopitant (VPD-737)
Indication: Psoriasis
- Menlo Therapeutics Inc.
- Neurokinin-1 Receptor Antagonists
Name: Upadacitinib (ABT-494)
Indication: PsA
- Abbvie
- JAK inhibitor
Topicals
Name: Roflumilast (ARQ-151) cream
Indication: Psoriasis
- Arcutis Biotherapeutics
- PDE4 Enzyme Inhibitor
Name: M518101
Indication: Psoriasis
- Maruho Co. Ltd.
Name: MC2-01 Cream
Indication: Psoriasis
- MC2 Therapeutics
- Calcipotriene and betamethasone dipropionate
Name: Tapinarof (DVMT-505)
Indication: Psoriasis
- Dermavant Sciences, Inc
- AhR agonist